search
Back to results

Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study

Primary Purpose

Nocturia

Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
[14C]-SK-1404
Sponsored by
Sanwa Kagaku Kenkyusho Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Nocturia focused on measuring nocturnal polyuria

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy males
  2. Age 30 to 65 years of age
  3. Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator
  4. Must be willing and able to communicate and participate in the whole study
  5. Must provide written informed consent
  6. Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per day)
  7. Must agree to use an adequate method of contraception

Exclusion Criteria:

  1. Males with pregnant partners
  2. Participation in a clinical research study within the 3 months prior to IMP dose
  3. Subjects who are study site employees, or immediate family members of a study site or sponsor employee
  4. Subjects who have previously been enrolled in this study
  5. Subjects who have previously been dosed with SK-1404
  6. History of any drug or alcohol abuse in the past 2 years
  7. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) in the past year
  8. Current smokers and those who have smoked within the last 12 months; this includes cigarettes, e-cigarettes and nicotine replacement products. A breath carbon monoxide reading of greater than 10 ppm at screening or admission
  9. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
  10. Subjects who have been enrolled in an ADME study in the last 12 months
  11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
  12. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1)
  13. Aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase >1.5 × upper limit of normal confirmed by repeat testing
  14. Serum sodium below the lower limit of normal

Sites / Locations

  • Quotient Clinical

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

[14C]-SK-1404

Arm Description

Outcomes

Primary Outcome Measures

Absolute bioavailability (F) calculated with the AUC values of IV administration in Part 1 and PO administration in Part 2
Mass balance recovery of total radioactivity in urine, faeces and all excreta
Amount excreted (Ae), and Ae as a percentage of the administered dose (%Ae), cumulative recovery (Cum Ae) and cumulative recovery expressed as a percentage of the dose (Cum %Ae)
Number and structural identification of known and unknown metabolites of SK-1404 in the plasma, urine and faeces samples

Secondary Outcome Measures

Ae total radioactivity in plasma by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
%Ae total radioactivity in plasma by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Cum Ae (total) for urine by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Cum %Ae (total) for urine by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Cum Ae (total) for faeces by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Cum %Ae (total) for faeces by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Number and structural identification of unknown metabolites of SK-1404 with an AUC of more than 10% of circulating total radioactivity
The peak plasma concentration (Cmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The time from dosing at which Cmax was apparent (Tmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The elapsed time from dosing at which the analyte was first quantifiable in a concentration vs time profile (Tlag) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The area under the concentration-time curve from dosing to the last measurable concentration (AUC(0-last)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The area under the concentration-time curve from dosing extrapolated to infinity (AUC(0-inf)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The percentage of AUC(0-inf) extrapolated beyond the last measured time point (AUC%extrap) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The terminal elimination rate constant calculated from the slope of the apparent elimination phase (lambda-z) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The apparent terminal elimination half-life (T1/2) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The apparent total clearance (CL/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The apparent volume of distribution (Vd) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The apparent volume of distribution (Vss) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The mean residence time (MRT) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The peak plasma concentration (Cmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The time from dosing at which Cmax was apparent (Tmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The elapsed time from dosing at which the analyte was first quantifiable in a concentration vs time profile (Tlag) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The area under the concentration-time curve from dosing to the last measurable concentration (AUC(0-last)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The area under the concentration-time curve from dosing extrapolated to infinity (AUC(0-inf)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The percentage of AUC(0-inf) extrapolated beyond the last measured time point (AUC%extrap) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The terminal elimination rate constant calculated from the slope of the apparent elimination phase (lambda-z) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The apparent terminal elimination half-life (T1/2) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The absolute bioavailability (F, PO vs IV from Part 1) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The apparent total clearance (CL/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The apparent volume of distribution (Vd/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
The mean residence time (MRT) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
To collect further information about the safety and tolerability of IMP
By assessing physical examination, safety laboratory tests, vital signs, electrocardiograms (ECGs) and AEs.

Full Information

First Posted
August 5, 2016
Last Updated
October 12, 2016
Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02878096
Brief Title
Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study
Official Title
An Open-Label, 2-Part Sequential Dose Study Designed to Assess the Absolute Bioavailability, Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1404 Administered to Healthy Male Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
July 2016 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
August 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objectives of the study are: To determine the absolute bioavailability of SK-1404 To assess the mass balance recovery after a single oral (PO) dose of carbon-14 (14C)-SK-1404 To provide plasma, urine and faecal samples for metabolite profiling and structural identification The secondary objectives of the study are: To determine the routes and rates of elimination of [14C]-SK-1404 To identify the chemical structure of each metabolite with an exposure (AUC) of more than 10% of circulating total radioactivity To explore the intravenous (IV) pharmacokinetics (PK) of [14C]-SK-1404 To further explore the PO PK of SK-1404 To provide additional safety and tolerability information for SK-1404
Detailed Description
This is a single-centre, 2-part, open-label, non-randomised, sequential, single dose study in healthy male subjects. It is planned to enrol a single cohort of 6 healthy male subjects who will participate in Parts 1 and Part 2 of the study. In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404. In Part 2, each subject will receive a single PO dose of [14C]-SK-1404.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nocturia
Keywords
nocturnal polyuria

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
[14C]-SK-1404
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
[14C]-SK-1404
Intervention Description
In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.
Primary Outcome Measure Information:
Title
Absolute bioavailability (F) calculated with the AUC values of IV administration in Part 1 and PO administration in Part 2
Time Frame
Predose to 96hr
Title
Mass balance recovery of total radioactivity in urine, faeces and all excreta
Description
Amount excreted (Ae), and Ae as a percentage of the administered dose (%Ae), cumulative recovery (Cum Ae) and cumulative recovery expressed as a percentage of the dose (Cum %Ae)
Time Frame
Predose to 168hr
Title
Number and structural identification of known and unknown metabolites of SK-1404 in the plasma, urine and faeces samples
Time Frame
Predose to 168hr
Secondary Outcome Measure Information:
Title
Ae total radioactivity in plasma by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Time Frame
Predose to 168hr
Title
%Ae total radioactivity in plasma by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Time Frame
Predose to 168hr
Title
Cum Ae (total) for urine by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Time Frame
Predose to 168hr
Title
Cum %Ae (total) for urine by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Time Frame
Predose to 168hr
Title
Cum Ae (total) for faeces by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Time Frame
Predose to 168hr
Title
Cum %Ae (total) for faeces by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Time Frame
Predose to 168hr
Title
Number and structural identification of unknown metabolites of SK-1404 with an AUC of more than 10% of circulating total radioactivity
Time Frame
Predose to 168hr
Title
The peak plasma concentration (Cmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The time from dosing at which Cmax was apparent (Tmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The elapsed time from dosing at which the analyte was first quantifiable in a concentration vs time profile (Tlag) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The area under the concentration-time curve from dosing to the last measurable concentration (AUC(0-last)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The area under the concentration-time curve from dosing extrapolated to infinity (AUC(0-inf)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The percentage of AUC(0-inf) extrapolated beyond the last measured time point (AUC%extrap) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The terminal elimination rate constant calculated from the slope of the apparent elimination phase (lambda-z) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The apparent terminal elimination half-life (T1/2) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The apparent total clearance (CL/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The apparent volume of distribution (Vd) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The apparent volume of distribution (Vss) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The mean residence time (MRT) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 96hr
Title
The peak plasma concentration (Cmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The time from dosing at which Cmax was apparent (Tmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The elapsed time from dosing at which the analyte was first quantifiable in a concentration vs time profile (Tlag) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The area under the concentration-time curve from dosing to the last measurable concentration (AUC(0-last)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The area under the concentration-time curve from dosing extrapolated to infinity (AUC(0-inf)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The percentage of AUC(0-inf) extrapolated beyond the last measured time point (AUC%extrap) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The terminal elimination rate constant calculated from the slope of the apparent elimination phase (lambda-z) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The apparent terminal elimination half-life (T1/2) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The absolute bioavailability (F, PO vs IV from Part 1) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The apparent total clearance (CL/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The apparent volume of distribution (Vd/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
The mean residence time (MRT) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Description
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Time Frame
Predose to 168hr
Title
To collect further information about the safety and tolerability of IMP
Description
By assessing physical examination, safety laboratory tests, vital signs, electrocardiograms (ECGs) and AEs.
Time Frame
Predose to 168hr

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy males Age 30 to 65 years of age Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator Must be willing and able to communicate and participate in the whole study Must provide written informed consent Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per day) Must agree to use an adequate method of contraception Exclusion Criteria: Males with pregnant partners Participation in a clinical research study within the 3 months prior to IMP dose Subjects who are study site employees, or immediate family members of a study site or sponsor employee Subjects who have previously been enrolled in this study Subjects who have previously been dosed with SK-1404 History of any drug or alcohol abuse in the past 2 years Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) in the past year Current smokers and those who have smoked within the last 12 months; this includes cigarettes, e-cigarettes and nicotine replacement products. A breath carbon monoxide reading of greater than 10 ppm at screening or admission Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study Subjects who have been enrolled in an ADME study in the last 12 months Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1) Aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase >1.5 × upper limit of normal confirmed by repeat testing Serum sodium below the lower limit of normal
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Litza McKenzie, MBChB BScMedSci
Organizational Affiliation
Quotient Clinical
Official's Role
Principal Investigator
Facility Information:
Facility Name
Quotient Clinical
City
Ruddington
State/Province
Nottingham
ZIP/Postal Code
NG11 6JS
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study

We'll reach out to this number within 24 hrs